Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Segments Reporting) (Details)

v3.21.2
Segment Reporting (Segments Reporting) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 10, 2021
Jun. 30, 2021
Segment Reporting Information [Line Items]        
Revenues - external customers $ 211 $ 410    
Revenues - intersegment 0 0    
Cost of goods sold 40 107    
Gross profit 171 303    
Research and development 2,511 1,862    
General and administrative 6,634 5,365    
Operating loss (8,974) (6,924)    
Interest expense (609) (614)    
Forgiveness of note payable and accrued interest - SBA loan 607 0    
Interest and other income 36 4    
Consolidated net loss (8,940) (7,534)    
Total assets 143,739 117,255   $ 146,968
Finance lease ROU assets 25,695 27,201   26,111
Operating lease right-of-use asset 3,487   $ 3,487 0
Fixed assets, net of accumulated depreciation 9,821 3,834   8,628
Intangible assets, net of accumulated amortization 5,164 1,236   $ 952
Amortization of finance lease ROU assets 416 415    
Depreciation of fixed assets 306 97    
Amortization of intangible assets 88 72    
Operating Segments [Member] | Biopharmaceuticals (iBio, Inc.) [Member]        
Segment Reporting Information [Line Items]        
Revenues - external customers 84 207    
Revenues - intersegment 82 238    
Cost of goods sold 0 54    
Gross profit 166 338    
Research and development 1,521 235    
General and administrative 3,484 2,672    
Operating loss (4,839) (2,569)    
Interest expense 0 0    
Forgiveness of note payable and accrued interest - SBA loan 0      
Interest and other income 36 3    
Consolidated net loss (4,802) (2,566)    
Total assets 176,682 132,207    
Finance lease ROU assets 0 0    
Operating lease right-of-use asset 3,487      
Fixed assets, net of accumulated depreciation 0 0    
Intangible assets, net of accumulated amortization 5,164 1,236    
Amortization of finance lease ROU assets 0 0    
Depreciation of fixed assets 0 0    
Amortization of intangible assets 88 72    
Operating Segments [Member] | Bioprocessing (iBio CDMO) [Member]        
Segment Reporting Information [Line Items]        
Revenues - external customers 127 203    
Revenues - intersegment 455 210    
Cost of goods sold 40 53    
Gross profit 542 413    
Research and development 1,467 1,845    
General and administrative 3,210 2,923    
Operating loss (4,135) (4,355)    
Interest expense (609) (614)    
Forgiveness of note payable and accrued interest - SBA loan 607      
Interest and other income 0 1    
Consolidated net loss (4,138) (4,968)    
Total assets 37,335 33,320    
Finance lease ROU assets 25,695 27,201    
Operating lease right-of-use asset 0      
Fixed assets, net of accumulated depreciation 9,821 3,834    
Intangible assets, net of accumulated amortization 0 0    
Amortization of finance lease ROU assets 416 415    
Depreciation of fixed assets 306 97    
Amortization of intangible assets 0 0    
Eliminations [Member]        
Segment Reporting Information [Line Items]        
Revenues - external customers 0 0    
Revenues - intersegment (537) (448)    
Cost of goods sold 0 0    
Gross profit (537) (448)    
Research and development (477) (218)    
General and administrative (60) (230)    
Operating loss 0 0    
Interest expense 0 0    
Forgiveness of note payable and accrued interest - SBA loan 0      
Interest and other income 0 0    
Consolidated net loss 0 0    
Total assets (70,278) (48,272)    
Finance lease ROU assets 0 0    
Operating lease right-of-use asset 0      
Fixed assets, net of accumulated depreciation 0 0    
Intangible assets, net of accumulated amortization 0 0    
Amortization of finance lease ROU assets 0 0    
Depreciation of fixed assets 0 0    
Amortization of intangible assets $ 0 $ 0